Oxcarbazepine in neuropathic pain

Bibliography

• SMITH TE, CHONG MS: Neuropathic pain. Hosp. Med. (2000) 61:760-766.
   PubMed Web of Science ®Google Scholar
• VAILLANCOURT PD, LANGEVIN HM: Painful peripheral neuropathies. Med. Clin. North Am. (1999) 83:627-642.
   PubMed Web of Science ®Google Scholar
• GALER BS, GIANAS A, JENSEN ME: Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res. Clin. Pract. (2000) 47:123-128.
   PubMed Web of Science ®Google Scholar
• CLARK MR, HEINBERG LJ, HAYTHORNTHWAITE JA et al.: Psychiatric symptoms and distress differ between patients with postherpetic neuralgia and peripheral vestibular disease. J. Psychomat. Res. (2000) 48:51-57.
   PubMed Web of Science ®Google Scholar
• MEYER-ROSBERG K, BURCKHARDT CS, HUIZAR K et al.: A comparison of the SF-36 and Nottingham health profile in patients with chronic neuropathic pain. Eur. J. Pain (2001) 5:391-403.
   PubMed Web of Science ®Google Scholar
• DOUGHERTY PM, GARRISON CJ, CARLTON SM: Differential influence of local anesthetic upon two models of experimentally induced peripheral mononeuropathy in the rat. Brain Res. (1992) 570:109-115.
   PubMed Web of Science ®Google Scholar
• BRIDGES D, THOMPSON SW, RICE AS: Mechanisms of neuropathic pain. Br. J. Anaesth. (2001) 87:12-26.
   PubMed Web of Science ®Google Scholar
• CAMPBELL JN, MEYER RA: Mechanisms of neuropathic pain. Neuron (2006) 52(1):77-92.
   PubMed Web of Science ®Google Scholar
• DEVOR M: Neuropathic pain and injured nerve: peripheral mechanisms. Br. Med. Bull. (1991)47:619-630.
   PubMed Web of Science ®Google Scholar
• DEVOR M, GOVRIN-LIPPMANN R, ANGELIDES K: Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J. Neurosci. (1993)13:1976-1992.
   PubMed Web of Science ®Google Scholar
• SATO J, PERL ER: Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science (1991) 251:1608-1610.
   PubMed Web of Science ®Google Scholar
• XIE YK, XIAO WH, LI HQ: The relationship between new ion channels and ectopic discharges from a region of nerve injury. Sci. China B (1993) 36:68-74.
   PubMedGoogle Scholar
• TAYLOR S: Epidemiology of refractory neuropathic pain. Pain Pract. (2006) 6:22-26.
   PubMedGoogle Scholar
• ZIEGLER D, GRIES FA, SPULER M, LESSMANN F: The epidemiology of diabetic neuropathy. J. Diab. Comp. (1992) 6:49-57.
   Google Scholar
• CAREY TS, EVANS AT, HADLER NM et al.: Acute severe low back pain. A population-based study of prevalence and care-seeking. Spine (1996) 21:339-344.
   PubMed Web of Science ®Google Scholar
• LONEY PL, STRATFORD PW: The prevalence of low back pain in adults: a methodological review of the literature. Phys. Ther. (1999) 79:384-396.
   PubMed Web of Science ®Google Scholar
• BERGER A, DUKES EM, OSTER G: Clinical characteristics and economic costs patients with painful neuropathic disorders. J. Pain (2004) 5:143-149.
   PubMed Web of Science ®Google Scholar
• DAVIES HT, CROMBIE IK, MCCRAE WA: Polarised views on treating neuropathic pain. Pain (1993)54:341-346.
   PubMed Web of Science ®Google Scholar
• ROWBOTHAM MC, GOLI V, KUNZ NR, LEI D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain (2004) 110:697-706.
   PubMed Web of Science ®Google Scholar
• RASKIN J, PRITCHETT YL, WANG F et al.: A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. (2005) 5:346-356.
   Google Scholar
• WERNICKE JF, PRITCHETT YL, D'SOUZA DN et al.: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology (2006) 67(8):1411-1420.
   PubMed Web of Science ®Google Scholar
• BACKONJA M, BEYDOUN A, EDWARDS KR et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA (1998) 280:1831-1183.
   PubMed Web of Science ®Google Scholar
• ROWBOTHAM M, HARDEN N, STACEY B, BERSTEIN P, MAGNUS-MILLER L: Gabapentin for the treatment of post-herpetic neuralgia: a randomized controlled trial. JAMA (1998) 280:1837-1842.
   PubMed Web of Science ®Google Scholar
• EISENBERG E, LURIE Y, BRAKER C, DAOUD DA, ISHAY A: Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology (2001) 57:505-509.
   PubMed Web of Science ®Google Scholar
• LESSER H, SHARMA U, LAMOREAUX L, POOLE RM: Pregabalin relieves symptoms of painful diabetic neuropathy. A randomized controlled trial. Neurology (2004) 63:2104-2110.
   PubMed Web of Science ®Google Scholar
• HARATI Y, GOOCH C, SWENSON M et al.: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology (1998) 50(6):1842-1846.
   PubMed Web of Science ®Google Scholar
• PORTENOY RK, FOLEY KM, INTURRISI CE: The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain (1990) 43:273-286.
   PubMed Web of Science ®Google Scholar
• KARCESKI S, MORRELL MJ, CARPENTER D: Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. (2005) 7(Suppl. 1):S1-S64.
   PubMed Web of Science ®Google Scholar
• DAM M, EKBERG R, LOYNING Y et al.: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. (1989) 3:70-76.
   PubMed Web of Science ®Google Scholar
• CRAWFORD P: Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs (2002) 16(4):263-272.
   PubMed Web of Science ®Google Scholar
• MCLEAN MJ, SCHMUTZ M, WAMIL AW et al.: Oxcarbazepine: mechanisms of action. Epilepsia (1994) 35(Suppl. 3):S5-S9.
   PubMed Web of Science ®Google Scholar
• CALABRESI P, DEMURTAS M, STEFANI A et al.: Action of GP47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia (1995) 36:990-996.
   PubMed Web of Science ®Google Scholar
• WHITE HS: Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia (1999) 40(Suppl. 5):S1-S83.
   Google Scholar
• SCHMUTZ M, BRUGGER M, GENTSCH C et al.: Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms action. Epilepsia (1994) 35(Suppl. 5):S47-S50.
   PubMed Web of Science ®Google Scholar
• SCHMIDT D, ELGER CE: What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav. (2004) 5:627-635.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA K, KOYAMA N, KIGUCHI S, KOJIMA M, YOKATA T: Inhibitory effect of oxcarbazepine on high-frequency firing in peripheral nerve fibres. Eur. J. Pharmacol. (2001) 420:119-122.
   PubMed Web of Science ®Google Scholar
• STEFANI A, PISANI A, DE MURTAS M, MERCURI NB, MARCIANI MG, CALABRESI P: Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia (1995) 36:997-1002.
   PubMed Web of Science ®Google Scholar
• WAMIL A, PORTET C, JENSEN PK, SCHMUTZ M, MCLEAN MJ: Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture. Epilepsia (1991) 32:65-66.
   Google Scholar
• FLESCH G: Overview of the clinical pharmacokinetics of oxcarbazepine. Clin. Drug Invest. (2004) 24:185-203.
   PubMed Web of Science ®Google Scholar
• MAY TW, KORN-MERKER E, RAMBECK B: Clinical pharmacokinetics of oxcarbazepine. Clin. Pharmacokinet. (2003) 42:1023-1042.
   PubMed Web of Science ®Google Scholar
• BIALER M: Oxcarbazepine: chemistry, biotransformation, and pharmacokinetics. In: Antiepileptic Drugs (5th Edition). Levy RH, Mattson RH, Meldrum BS et al. (Eds). Lippincott Williams & Wilkins, Philadelphia, USA (2002):459-465.
   Google Scholar
• FOX A, GENTRY C, PATEL S, KESINGLAND A, BEVAN S: Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. Pain (2003) 105:355-362.
   PubMed Web of Science ®Google Scholar
• JANG Y, KIM E, PARK S, LEE J, MOON D: The suppressive effects of oxcarbazepine on mechanical and cold Allodynia in a rat model of neuropathic pain. Anesth. Analg. (2005) 101:800-806.
   PubMed Web of Science ®Google Scholar
• DOGRA S, BEYDOUN S, MAZZOLA J, HOPWOOD M, WAN Y: Oxcarbazepine in painful diabetic neuropathy: a randomized placebo-controlled study. Eur. J. Pain (2005) 9:543-554.
   PubMed Web of Science ®Google Scholar
• BEYDOUN A, SHAIBANI A, HOPWOOD M, WAN Y: Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol. Scand. (2006) 113:395-404.
   PubMed Web of Science ®Google Scholar
• GROSSKOPF J, MAZZOLA J, WAN Y, HOPWOOD M: A randomised, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol. Scand. (2006) 114(3):177-180.
   PubMed Web of Science ®Google Scholar
• ZAKRZEWSKA JM, PATSALOS PN: Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J. Neurol. Neurosurg. Psychiatry (1989) 52(4):472-476.
   PubMed Web of Science ®Google Scholar
• FARAGO F: Trigeminal neuralgia: its treatment with two new carbamazepine analogues. Eur. Neurol. (1987) 26:73-83.
   PubMed Web of Science ®Google Scholar
• REMILLARD G: Oxcarbazepine and intractable trigeminal neuralgia. Epilepsia (1994) 35(Suppl. 3):S28-S29.
   Web of Science ®Google Scholar
• LINDSTROM P: The analgesic effect of carbamazepine in trigeminal neuralgia. Pain (1987) 30:S85.
   Google Scholar
• BEYDOUN A, SCHMIDT D, D'SOUZA J; ON BEHALF OF THE OXCARBAZEPINE STUDY GROUP: Meta-analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. Poster Presented at the 21st American Pain Society Annual Meeting, Baltimore, USA (14 – 17 March 2002).
   Google Scholar
• MAGENTA P, ARGHETTI S, DI PALMA et al.: Oxcarbazepine is effective and safe in the treatment of neuropathic pain: pooled analysis of seven clinical studies. Neurol. Sci. (2005) 26:218-226.
   PubMed Web of Science ®Google Scholar
• BEYDOUN A, SACHDEO RC, ROSENFELD WE et al.: Oxcarbazepine monotherapy for partial onset seizures: a multicenter, double-blind, clinical trial. Neurology (2000) 54:2245-2251.
   PubMed Web of Science ®Google Scholar
• NOVARTIS PHARMACEUTICALS CORP.: Trileptal. Product monograph. New first-line antiepileptic drug. (May 2000).
   Google Scholar
• KUTLUAY E, MCCAGUE K, D'SOUZA J et al.: Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav. (2003) 4:175-180.
   PubMed Web of Science ®Google Scholar
• SACHDEO RC, WASSERSTEIN A, MESENBRINK PJ et al.: Effects of oxcarbazepine on sodium concentration and water handling. Ann. Neurol. (2002) 51:613-620.
   PubMed Web of Science ®Google Scholar
• KRAMER L: Clinical expert report on the clinical documentation Trileptal®. Data on File. Novartis, Basel, Switzerland.
   Google Scholar
• ALTMAN D, MARTIN B: Absence of evidence is not evidence of absence. Br. Med. J. (1995) 311:485.
   PubMed Web of Science ®Google Scholar
• FARRAR JT, BERLIN JA, STROM BL: Clinically inportant changes in acute pain outcome meaures: a validation study. J. Pain Symp. Manage. (2003) 25:406-411.
   PubMed Web of Science ®Google Scholar
• BEYDOUN A, BACKONJA M: Mechanistic stratification of antineuralgic agents. J. Pain Symp. Manage. (2003) 25:S18-S30.
   PubMedGoogle Scholar